COSELA^® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

G1 Therapeutics, Inc. announced that the China National Medical Products Administration has conditionally approved COSELA, which was jointly developed for use in Greater China by Simcere and G1 Therapeutics.